Fenebrutinib (GDC-0853) HCl

Fenebrutinib (GDC-0853) HCl Suppliers list
Company Name: InvivoChem
Tel: +1-708-310-1919 +1-13798911105
Email: sales@invivochem.cn
Products Intro: Product Name:Fenebrutinib (GDC-0853) HCl
CAS:2128304-54-9
Purity:98% Package:5mg Remarks:V4148
Company Name: InvivoChem  
Tel: 13549236410
Email: sales@invivochem.cn
Products Intro: Product Name:Fenebrutinib (GDC-0853) HCl
CAS:2128304-54-9
Purity:98% HPLC Package:1mg Remarks:V4148
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Products Intro: Product Name:Fenebrutinib HCl
CAS:2128304-54-9
Purity:0 Package:25mg/RMB 10600
Fenebrutinib (GDC-0853) HCl Basic information
Product Name:Fenebrutinib (GDC-0853) HCl
Synonyms:Fenebrutinib (GDC-0853) HCl;Fenebrutinib HCl;RG 7845;RG7845;RG-7845
CAS:2128304-54-9
MF:C37H45ClN8O4
MW:701.27
EINECS:
Product Categories:
Mol File:2128304-54-9.mol
Fenebrutinib (GDC-0853) HCl Structure
Fenebrutinib (GDC-0853) HCl Chemical Properties
Safety Information
MSDS Information
Fenebrutinib (GDC-0853) HCl Usage And Synthesis
DescriptionFenebrutinib, also known as GDC-0853, is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, GDC-0853 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.
Fenebrutinib (GDC-0853) HCl Preparation Products And Raw materials
Tag:Fenebrutinib (GDC-0853) HCl(2128304-54-9) Related Product Information